Tolvaptan as A treatment for Refractory Cirrhotic Ascites in Japanese population (TARCAJa study)

Tolvaptan as A treatment for Refractory Cirrhotic Ascites in Japanese population (TARCAJa study) - Tolvaptan as A treatment for Refractory Cirrhotic Ascites in Japanese population(TARCAja study)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020094

Enrollment

200

Registered

2015-12-07

Start date

2015-12-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhotic patients with ascites unresponsive to standard diuretic therapy

Interventions

administration of tolvaptan(3.75-7.5mg/day)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Obtained informed consent form from patients. Unresponsiveness to standard diuretic therapies.

Exclusion criteria

Exclusion criteria: Alergy to tolvaptan. Renal failure patients. Diffcult to drink water. Hypernatremia patients. Heptatic encephalopathy patients. Pregnancy. Other patients who doctors judged as not suitable for this study.

Design outcomes

Primary

Measure	Time frame
Alterlation of ascites and hyponatremia	—

Secondary

Measure	Time frame
Overall survival, safty, and changes in parameter	—

Countries

Japan

Contacts

Public ContactTakamasa Ohki

Mitsui Memorail Hospital Gastroenterology

anb72547@nifty.com03-3862-9111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026